Clinical trials: Non-Alcoholic Fatty Liver Disease
Inflammation, Fibrosis
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We aim to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD.
- Conditions
- Inflammation, Fibrosis, Insulin Resistance
- Trial name
- VITENAFLD (NCT00655018)
- Testing
- Vitamin treatment (alpha tocopherol plus ascorbic acid)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of the leptin replacement therapy in treating lipoatrophy or lipodystrophy-a condition in which there is a total or partial loss of fat cells.
- Trial name
- NCT00005905
- Testing
- hu Leptin (A-100)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Nonalcoholic Steatohepatitis
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00013598
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Phase I Trial of Silymarin for Chronic Liver Diseases
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
- Trial name
- SyNCH (NCT00389376)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Fatty Liver, Hepatitis
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic…
- Trial name
- NCT00160407
- Testing
- Orlistat (Xenical), 1400 kcal diet (30% fat)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Louis University
Fatty Liver
Metformin in Non-Alcoholic Fatty Liver Disease
The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.
- Trial name
- NCT00303537
- Testing
- metformin
- Where
- 4 sites in Norway
- Volunteers
- 90 people
- Sponsor
- University Hospital, Aker
Non Alcoholic Steatohepatitis
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- FLIRT (NCT00492700)
- Testing
- rosiglitazone
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Association pour la Recherche sur les Maladies Hépatiques Virales
Sleep Apnea Syndrome, Nonalcoholic Steatohepatitis
Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis
This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatitis.
- Trial name
- NCT00152711
- Testing
- nCPAP
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Angers
Liver Diseases
Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.
- Trial name
- NCT00247117
- Testing
- Metformin
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Kaplan Medical Center
Morbid Obesity, Metabolic Disease
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. Patients with this syndrome are at increased risk for cardiovascular disease, and at increased risk of mortality…
- Trial name
- NCT00283374
- Testing
- Laparoscopic Roux-en-Y Gastric Bypass
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer